BRL-50481
PDE7 inhibitor / Potent and selective inhibitor of phosphodiesterase-7 (PDE7), Ki=180 nM1. Induces apoptosis in chronic lymphocytic leukemia cells which express PDE7B2. Increases mineralization in osteoblasts differentiated from hMSC3. Cell permeable.
Biochemicals & reagents
433695-36-4
1) Smith et al. (2004), Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages and CD8+ T-lymphocytes; Mol. Pharmacol., 66 1679 2) Zhang et al. (2008), Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia; Proc. Natl. Acad. Sci. USA 105 19532 3) Pekkinen et al. (2008), Effects of phosphodiesterase 7 inhibition by RNA interference on the gene expression and differentiation of human mesenchymal stem cell-derived osteoblasts; Bone, 43 84
RT
TARGET: PDE (Phosphodiesterase) -- PATHWAY: Apoptosis inducer; cAMP / cGMP signaling -- RESEARCH AREA: Cell death -- DISEASE AREA: Cancer